STK-009/SYNCAR-002 / Synthekine - LARVOL DELTA

Orthogonal IL-2/IL-2Rβ signaling selectively enhances and sustains a synthetic effector state via a novel mechanism and outperforms constitutive armoring approaches (AACR 2024) - P1 | "In a HCC tumor model, treatment with STK-009/SYNCAR-002 demonstrated superior tumor control with minimal toxicities. Interestingly, IL-18 overexpression also controlled tumors, but was accompanied by uncontrolled CAR T cell expansion and toxicity resembling severe GVHD.scRNAseq analyses revealed STK-009-treated SYNCAR-002 T cells simultaneously activated effector genes and repressed an exhaustion gene signature. This analysis also identified a novel mechanism by which STK-009/oRβ signaling induces a superior synthetic effector state via transcriptional repression of the stress response/proteosome.These findings support the advantages of an orthogonal platform that selectively drives and sustains potent T cell effector function without safety concerns associated with constitutively expressed armored approaches."

Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Lymphoma • Oncology • Solid Tumor • GPC3 • IL15 • IL18 • IL2 • IL2RA • JUN

Orthogonal IL-2/IL-2R β Armoring is Superior to TGF-β Receptor Blockade in Overcoming TGF-β-Driven Inhibition of GPC3 CAR T Cells in Hepatocellular Carcinoma (ASGCT 2025) - P1 | "STK-009/SYNCAR-002 treatment demonstrated superior tumor control, cell proliferation, and better cell fitness compared to the DNTGFBRII armored CAR T cells. These findings support the advantage of an orthogonal IL-2/IL-2R system that selectively drives and sustains potent T cell effector function even in an adverse tumor microenvironment saturated with TGF-β. Disease Focus of Abstract:Cancer Solid Tumors"

CAR T-Cell Therapy • Hematological Malignancies • Hepatocellular Cancer • Lymphoma • Oncology • Solid Tumor • IFNG • IL2RA • TGFB1